ION BEAM Aktie

 

MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, today announced a collaboration to advance scalable United States (U.S.) production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy....

Der belgische Radiopharma-Spezialist Ion Beam Applications (IBA) hat in der zurückliegenden Handelswoche erneut für positiven Newsflow gesorgt. Das spiegelt sich in steigenden Notierungen beim AKTIONÄR-Hot-Stock wider, der das 52-Wochen-Hoch wieder ansteuert....

Louvain-la-Neuve, Belgium, and Paris, France, 16 October 2026, 8:00 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and radiopharmaceutical production solutions, and Framatome, an international leader in nuclear energy committed, among other activities, to the industrial development of products and services for human health through its Framatome Healthcare brand, today announce the establishment of a joint venture (JV) named Ekalia, with its dedicated logo:...

Louvain-La-Neuve, Belgium, September 29, 2026 at 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena (IFO), to provide a turnkey proton therapy solution in Rome, Italy. The center will be the first gantry-based proton therapy system available in central and southern Italy....

Louvain-la-Neuve, Belgium, 25 September 2026, 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces it will coordinate the LIFEDESTINY, a new European LIFE project dedicated to tackling one of today's most persistent environmental challenges: PFAS contamination. The consortium will demonstrate a more sustainable, scalable and cost-effective approach to permanently degrading PFAS across different contaminated matrices....

Der Einsatz von umstrittenen PFAS (per- und polyfluorierte Alkylsubstanzen) ist auch in der Healthcare-Branche ein Problem. Mit der europäischen Initiative PFAROS soll dieses nun verstärkt angegangen werden. Eine tragende Rolle bei dem Vorhaben nehmen der DAX-Konzern Bayer und die belgische Medizintechnik-Gesellschaft Ion Beam Applications ein....

Die Berichtssaison ist weitgehend vorbei. Nur noch wenige Unternehmen legen die Bilanzen für das vergangene Quartal beziehungsweise erste Halbjahr vor. So auch Ion Beam Applications, der belgische Radiopharma-Spezialist. Der Bericht für die ersten sechs Monate kann sich sehen lassen – vor allem im Hinblick auf die Ergebnisentwicklung....

Zahlreiche Medizintechnik-Aktien fristen im Schatten der großen Tech-Trends Halbleiter, KI und Co derzeit ein Schattendasein. Doch darin bestehen enorme Chancen für Anleger. So auch bei Ion Beam Applications. Die Aktie des belgischen Protonentherapie-Spezialisten lief viele Monate lethargisch seitwärts....

Louvain-La-Neuve, Belgium, June 30, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, announces today the entering into effect of a contract with Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), for the installation of two Proteus®ONE1 compact proton therapy solutions at the IPO-Porto facilities in Porto, Portugal. The two Proteus®ONE systems will be the first proton therapy systems in the country and will serve as the National Proton Therapy Center of Portugal....

Louvain-La-Neuve, Belgium, June 25, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Fundação Severino Sombra (FUSVE), a non-profit philanthropic healthcare and educational institution responsible for the University of Vassouras and Hospital Mário Kroeff, for the purchase of a Proteus®ONE1 system....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Louvain-la-Neuve, Belgium, 17 June 2026 - At its Board meeting held yesterday in Louvain-la-Neuve, IBA (Ion Beam Applications S.A., EURONEXT) welcomed two new Board members, acknowledged the departure of outgoing directors, and announced the payment of €0.25 dividend per share on July 1st....

Louvain-la-Neuve, Belgium, June 15th, 2026 – 6 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026....

Louvain-la-Neuve, Belgium, June 10, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of proton therapy solutions for the treatment of cancer, today announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center aimed at advancing health economics evidence generation for proton beam therapy....

Louvain-la-Neuve, Belgium, June 8th, 2026 – 6 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026....

Im schwachen Gesamtmarkt präsentiert sich die Aktie von Ion Beam Applications in einer starken Verfassung. Auch zum Start in die neue Handelswoche zeichnen sich im frühen Handel weitere Kursgewinne beim europäischen Nebenwert ab. Kein Wunder, konnten die Belgier einen weiteren nennenswerten Auftrag aus den USA an Land ziehen....

Louvain-La-Neuve, Belgium, June 08, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, today announces the signing of a contract with Duke University Health System for the installation of two Proteus®ONE1 compact proton therapy solutions at the Duke Proton Center in Durham, NC, USA....

Louvain-la-Neuve, Belgium, June 1st, 2026 – 9 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026....

Louvain-la-Neuve, Belgium – 01 June 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today launches Cyclone® iKure, a dedicated cyclotron for routine Astatine-211 (At-211) production. Designed for alpha-beam irradiation, this new cyclotron enables radiopharmaceutical manufacturers, research institutions and healthcare providers to accelerate access to targeted alpha therapies with the reliability and quality required for clinical-scale programs....

Louvain-la-Neuve, Belgium, May 26th, 2026 – 6 PM CEST – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026....